Pfizer Cherry-Picks Cancer Drug Rights From Merck

The video discusses the current attractiveness of assets in the pharmaceutical industry, focusing on a significant deal by Merck in the immuno-oncology space. It highlights the competitive landscape with major players like Roche, AstraZeneca, and Bristol Myers. The discussion also covers Pfizer's financial strategy, emphasizing their cash generation and potential shift towards tactical licensing deals rather than large mergers and acquisitions.

What factors could influence the success of the drug discussed in the deal?

What strategy might Pfizer be considering regarding their pipeline and drug development?